Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Operating Leases (2022 - 2025)

Historic Operating Leases for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $85000.0.

  • NewAmsterdam Pharma's Operating Leases fell 6804.51% to $85000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $85000.0, marking a year-over-year decrease of 6804.51%. This contributed to the annual value of $202000.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, NewAmsterdam Pharma's Operating Leases stood at $85000.0, which was down 6804.51% from $103000.0 recorded in Q2 2025.
  • Over the past 5 years, NewAmsterdam Pharma's Operating Leases peaked at $328000.0 during Q2 2024, and registered a low of $57133.8 during Q4 2022.
  • Over the past 4 years, NewAmsterdam Pharma's median Operating Leases value was $120000.0 (recorded in 2025), while the average stood at $155978.1.
  • Per our database at Business Quant, NewAmsterdam Pharma's Operating Leases soared by 37064.8% in 2024 and then crashed by 6859.76% in 2025.
  • NewAmsterdam Pharma's Operating Leases (Quarter) stood at $57133.8 in 2022, then increased by 21.98% to $69691.2 in 2023, then skyrocketed by 189.85% to $202000.0 in 2024, then plummeted by 57.92% to $85000.0 in 2025.
  • Its last three reported values are $85000.0 in Q3 2025, $103000.0 for Q2 2025, and $137000.0 during Q1 2025.